ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1517

Integrated Safety Analysis across Phase 3 Clinical Studies Including the Controlled and Uncontrolled Periods for Intravenous Golimumab in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

Arthur Kavanaugh1, Atul A. Deodhar2, Sergio Schwartzman3, Shelly Kafka4, Soumya D Chakravarty5, Elizabeth C Hsia6, Diane D. Harrison7, Jocelyn Leu7, Yiying Zhou7, Kim Hung Lo7 and M. Elaine Husni8, 1University of California, San Diego, School of Medicine, La Jolla, CA, 2Oregon Health & Science U, Portland, OR, 3Weill Cornell Medical College, New York, NY, 4Janssen Scientific Affairs, LLC, Horsham, PA, 5Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA, 6Janssen Reseach & Development, LLC/ U of Pennsylvania School of Medicine, Spring House/Philadelphia, PA, 7Janssen Research & Development, LLC, Spring House, PA, 8Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), Psoriatic arthritis, rheumatoid arthritis (RA) and safety

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The GO-FURTHER, GO-VIBRANT, and GO-ALIVE randomized controlled trials evaluated the efficacy and safety of intravenous (IV) golimumab (GLM) in patients (pts) with active rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS), respectively. This integrated analysis assessed safety events across indications in pts who received IV GLM.

Methods: Integrated safety data from 3 Phase 3, double-blind, placebo (PBO)-controlled trials were analyzed up to week (WK) 112 in RA pts and up to WK 60 in PsA and AS pts. Pts received either IV PBO or IV GLM (2 mg/kg) at 0, 4, 12, and 20 WKS. PBO pts crossed over to IV GLM at WK 24, except RA pts randomized to PBO who met early escape criteria crossed over at WK 16 and AS pts randomized to PBO who crossed over at WK 16. Cumulative adverse events (AEs) were reported by indication and pooled by treatment. Anti-drug antibodies (ADAs) were evaluated.

Results: Overall, 1248 pts were treated with IV GLM across indications. A numerically greater proportion (%) of IV GLM pts with RA reported safety events than pts with PsA or AS (Table 1): SAEs (18.2 vs 5.2 vs 3.4), infections (49.1 vs 22.8 vs 32.8), serious infections (6.2 vs 2.2 vs 1.5), and infusion reactions (4.6 vs 0.9 vs 1.5). Incidence (per 100 pt-years) of opportunistic infections, malignancy, active tuberculosis, and death with IV GLM was low (≤0.5) across indications (Table 2). Infections were the most commonly reported type of SAE among pooled IV GLM pts; the most frequent was pneumonia (10 [0.8%]). Incidence (per 100 pt-years) of serious infections was similar among IV GLM pts with and without corticosteroid use (3.35 vs 3.37, respectively). Overall, 1 IV GLM pt (PsA) experienced a demyelination event. A numerically greater proportion of IV GLM pts discontinued due to an AE than PBO pts (5.0% vs 0.9%, respectively). In IV GLM pts with baseline alanine aminotransferase (ALT) ≤ upper limit of normal (ULN), 1.2% had post-baseline ALT elevations ≥5X ULN. The proportion of IV GLM and PBO pts with post-baseline ALT elevations ≥5X ULN was 2.1% vs 0% with methotrexate and 0.7% vs 1.4% without methotrexate use at baseline, respectively. Using a drug-tolerant enzyme immunoassay, the incidence of ADAs was 22% through WK 52 across indications, which primarily consisted of low titer ADAs.

Conclusion: IV GLM demonstrated a consistent safety profile across indications in the PBO-controlled (up to WK 24) and uncontrolled study periods. Similar to WK 24, more safety events occurred in RA pts, who represented the largest study population with older pts, longer disease duration, and more concomitant medication use.

 


 

Table 1. Summary of Adverse Events During the Placebo-controlled and Uncontrolled Study Periods

Variables

RAa

PsAb

ASb

All

IV GLM

IV GLM

IV GLM

IV GLM

Treated patients, n

584

460

204

1248

Average duration of follow up, wks

95.9

47.2

51.8

70.7

Patients who discontinued due to

  an AE

41 (7.0)

17 (3.7)

4 (2.0)

62 (5.0)

Patients with ≥1 AE

462 (79.1)

234 (50.9)

113 (55.4)

809 (64.8)

Patients with ≥1 SAE

106 (18.2)

24 (5.2)

7 (3.4)

137 (11.0)

Patients with ≥1 infection

287 (49.1)

105 (22.8)

67 (32.8)

459 (36.8)

Patients with ≥1 serious infection

36 (6.2)

10 (2.2)

3 (1.5)

49 (3.9)

Patients with ≥1 infusion reaction

27 (4.6)

4 (0.9)

3 (1.5)

34 (2.7)

ADA-positive patientsc, %

23.4

22.0

20.2

22.3

Patients n (%) reporting safety events during the placebo-controlled and uncontrolled study periods are reported, unless otherwise specified.

aBased on safety events that occurred up to week 112

bBased on safety events that occurred up to week 60

cAssessed using a drug-tolerant enzyme immunoassay based on IV GLM patients with appropriate samples through week 52 (RA, n=552; PsA,
n=450; AS, n=203; and All, n=1205)

ADA, anti-drug antibody; AE, adverse event; AS, ankylosing spondylitis; IV GLM, intravenous golimumab; PsA, psoriatic arthritis; RA,
rheumatoid arthritis; SAE, serious adverse event

 

Table 2. Incidence of Safety Events Per 100 Patient-Years

Variables

RAa

PsAb

ASb

All

IV GLM

Placebo

IV GLM

Placebo

IV GLM

Placebo

IV GLM

Placebo

Treated patients, n

584

197

460

239

204

103

1248

539

Average duration of follow up, wks

95.9

21.0

47.2

23.2

51.8

16.1

70.7

21.0

Opportunistic infections

0.4

0

0

0

0

0

0.2

0

  (95% confidence interval)

(0.1, 1.0)

(0, 3.8)

(0, 0.7)

(0, 2.8)

(0, 1.5)

(0, 9.4)

(0.1, 0.6)

(0, 1.4)

All malignancies

0.5

0

0.5

1.9

0

0

0.4

0.9

  (95% confidence interval)

(0.2, 1.1)

(0, 3.8)

(0.1, 1.7)

(0.2, 6.8)

(0, 1.5)

(0, 9.4)

(0.2, 0.9)

(0.1, 3.3)

Active TB

0.2

0

0.5

0

0.5

0

0.3

0

  (95% confidence interval)

(0, 0.7)

(0, 3.8)

(0.1, 1.7)

(0, 2.8)

(0, 2.7)

(0, 9.4)

(0.1, 0.7)

(0, 1.4)

Death

0.5

1.3

0.2

1.9

0

0

0.4

1.4

  (95% confidence interval)

(0.2, 1.1)

(0, 7.0)

(0, 1.3)

(0.2, 6.8)

(0, 1.5)

(0, 9.4)

(0.1, 0.8)

(0.3, 4.0)

Incidence per 100 patient-years are reported, unless otherwise specified.

aBased on safety events that occurred up to week 112

bBased on safety events that occurred up to week 60

AS, ankylosing spondylitis; IV GLM, intravenous golimumab; PsA, psoriatic arthritis, RA, rheumatoid arthritis; TB, tuberculosis

 


Disclosure: A. Kavanaugh, Janssen Research Development, LLC, 2; A. A. Deodhar, Janssen Research & Development, LLC, 2; S. Schwartzman, Janssen Research & Development, LLC, 2; S. Kafka, Janssen Scientific Affairs, LLC, 3; S. D. Chakravarty, Janssen Scientific Affairs, LLC, 3; E. C. Hsia, Janssen Research & Development, LLC, 3; D. D. Harrison, Janssen Research & Development, LLC, 3; J. Leu, Janssen Research Development, LLC, 3; Y. Zhou, Janssen Research Development, LLC, 3; K. H. Lo, Janssen Research & Development, LLC, 3; M. E. Husni, Janssen Research & Development, LLC, 2.

To cite this abstract in AMA style:

Kavanaugh A, Deodhar AA, Schwartzman S, Kafka S, Chakravarty SD, Hsia EC, Harrison DD, Leu J, Zhou Y, Lo KH, Husni ME. Integrated Safety Analysis across Phase 3 Clinical Studies Including the Controlled and Uncontrolled Periods for Intravenous Golimumab in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/integrated-safety-analysis-across-phase-3-clinical-studies-including-the-controlled-and-uncontrolled-periods-for-intravenous-golimumab-in-rheumatoid-arthritis-psoriatic-arthritis-and-ankylosing-spon/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/integrated-safety-analysis-across-phase-3-clinical-studies-including-the-controlled-and-uncontrolled-periods-for-intravenous-golimumab-in-rheumatoid-arthritis-psoriatic-arthritis-and-ankylosing-spon/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology